The BE GONE trial study protocol: a randomized crossover dietary intervention of dry beans targeting the gut microbiome of overweight and obese patients with a history of colorectal polyps or cancer.
Colorectal cancer survivors
Diet
Dry beans
Gut microbiome
Metabolome
Obesity
Precancerous colorectal polyps
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
18 Dec 2019
18 Dec 2019
Historique:
received:
07
10
2019
accepted:
22
11
2019
entrez:
20
12
2019
pubmed:
20
12
2019
medline:
2
6
2020
Statut:
epublish
Résumé
Mouse and human studies support the promise of dry beans to improve metabolic health and to lower cancer risk. In overweight/obese patients with a history of colorectal polyps or cancer, the Beans to Enrich the Gut microbiome vs. Obesity's Negative Effects (BE GONE) trial will test whether and how an increase in the consumption of pre-cooked, canned dry beans within the context of usual diet and lifestyle can enhance the gut landscape to improve metabolic health and reduce cancer risk. This randomized crossover trial is designed to characterize changes in (1) host markers spanning lipid metabolism, inflammation, and obesity-related cancer risk; (2) compositional and functional profiles of the fecal microbiome; and (3) host and microbial metabolites. With each subject serving as their own control, the trial will compare the participant's usual diet with (intervention) and without (control) dry beans. Canned, pre-cooked dry beans are provided to participants and the usual diet continually assessed and monitored. Following a 4-week run-in and equilibration period, each participant provides a total of 5 fasting blood and 6 stool samples over a total period of 16 weeks. The intervention consists of a 2-week ramp-up of dry bean intake to 1 cup/d, which is then continued for an additional 6 weeks. Intra- and inter-individual outcomes are assessed across each crossover period with consideration of the joint or modifying effects of the usual diet and baseline microbiome. The BE GONE trial is evaluating a scalable dietary prevention strategy targeting the gut microbiome of high-risk patients to mitigate the metabolic and inflammatory effects of adiposity that influence colorectal cancer risk, recurrence, and survival. The overarching scientific goal is to further elucidate interactions between diet, the gut microbiome, and host metabolism. Improved understanding of the diet-microbiota interplay and effective means to target these relationships will be key to the future of clinical and public health approaches to cancer and other major diet- and obesity-related diseases. This protocol is registered with the U.S. National Institutes of Health trial registry, ClinicalTrials.gov, under the identifier NCT02843425. First posted July 25, 2016; last verified January 25, 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Mouse and human studies support the promise of dry beans to improve metabolic health and to lower cancer risk. In overweight/obese patients with a history of colorectal polyps or cancer, the Beans to Enrich the Gut microbiome vs. Obesity's Negative Effects (BE GONE) trial will test whether and how an increase in the consumption of pre-cooked, canned dry beans within the context of usual diet and lifestyle can enhance the gut landscape to improve metabolic health and reduce cancer risk.
METHODS/DESIGN
METHODS
This randomized crossover trial is designed to characterize changes in (1) host markers spanning lipid metabolism, inflammation, and obesity-related cancer risk; (2) compositional and functional profiles of the fecal microbiome; and (3) host and microbial metabolites. With each subject serving as their own control, the trial will compare the participant's usual diet with (intervention) and without (control) dry beans. Canned, pre-cooked dry beans are provided to participants and the usual diet continually assessed and monitored. Following a 4-week run-in and equilibration period, each participant provides a total of 5 fasting blood and 6 stool samples over a total period of 16 weeks. The intervention consists of a 2-week ramp-up of dry bean intake to 1 cup/d, which is then continued for an additional 6 weeks. Intra- and inter-individual outcomes are assessed across each crossover period with consideration of the joint or modifying effects of the usual diet and baseline microbiome.
DISCUSSION
CONCLUSIONS
The BE GONE trial is evaluating a scalable dietary prevention strategy targeting the gut microbiome of high-risk patients to mitigate the metabolic and inflammatory effects of adiposity that influence colorectal cancer risk, recurrence, and survival. The overarching scientific goal is to further elucidate interactions between diet, the gut microbiome, and host metabolism. Improved understanding of the diet-microbiota interplay and effective means to target these relationships will be key to the future of clinical and public health approaches to cancer and other major diet- and obesity-related diseases.
TRIAL REGISTRATION
BACKGROUND
This protocol is registered with the U.S. National Institutes of Health trial registry, ClinicalTrials.gov, under the identifier NCT02843425. First posted July 25, 2016; last verified January 25, 2019.
Identifiants
pubmed: 31852462
doi: 10.1186/s12885-019-6400-z
pii: 10.1186/s12885-019-6400-z
pmc: PMC6921460
doi:
Banques de données
ClinicalTrials.gov
['NCT02843425']
Types de publication
Clinical Trial Protocol
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
1233Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : University of Texas MD Anderson Cancer Center
ID : Institutional Research Grant
Organisme : NCI NIH HHS
ID : 5P30 CA016672-37
Pays : United States
Organisme : American Cancer Society
ID : RSG-17-049-01-NEC
Organisme : Cancer Prevention and Research Institute of Texas
ID : RP160097
Références
Nature. 2012 Jun 13;486(7402):207-14
pubmed: 22699609
Obes Rev. 2014 May;15(5):392-407
pubmed: 24433379
Semin Oncol. 2016 Feb;43(1):97-106
pubmed: 26970128
BMJ. 2018 Jun 13;361:k2179
pubmed: 29899036
Nature. 2013 Aug 29;500(7464):585-8
pubmed: 23985875
Nutr Cancer. 2016 Nov-Dec;68(8):1269-1280
pubmed: 27689688
Nutr Metab Cardiovasc Dis. 2011 Feb;21(2):94-103
pubmed: 19939654
Bioinformatics. 2015 Sep 1;31(17):2882-4
pubmed: 25957349
PLoS Comput Biol. 2009 Apr;5(4):e1000352
pubmed: 19360128
Gut. 2019 Jun;68(6):1108-1114
pubmed: 30670574
J Infect Dis. 2009 Feb 15;199(4):477-85
pubmed: 19128145
Gut. 2017 Oct;66(10):1790-1796
pubmed: 27436272
J Nutr. 2010 Jan;140(1):60-7
pubmed: 19889807
Am J Clin Nutr. 1986 Sep;44(3):390-7
pubmed: 3529917
Cancer Prev Res (Phila). 2012 Nov;5(11):1260-72
pubmed: 23034147
J Nutr. 2007 Nov;137(11):2391-8
pubmed: 17951475
Am J Clin Nutr. 2013 May;97(5):1036-43
pubmed: 23515007
Mol Nutr Food Res. 2017 Jan;61(1):
pubmed: 27461523
Curr Colorectal Cancer Rep. 2017 Dec;13(6):429-439
pubmed: 29333111
Expert Rev Gastroenterol Hepatol. 2015 Jun;9(6):781-95
pubmed: 25665875
Cancer Cell. 2018 Jun 11;33(6):954-964
pubmed: 29657127
Lipids. 2010 Sep;45(9):765-75
pubmed: 20734238
J Clin Oncol. 2013 Jun 20;31(18):2313-21
pubmed: 23690410
Cancer Causes Control. 2009 Dec;20(10):1955-66
pubmed: 19565341
Microb Ecol Health Dis. 2015 Feb 04;26:26164
pubmed: 25656825
Nat Rev Nephrol. 2016 Mar;12(3):169-81
pubmed: 26616538
Cancer. 2015 Sep 1;121(17):2968-75
pubmed: 25975416
Nature. 2014 Jan 23;505(7484):559-63
pubmed: 24336217
Cancer Cell. 2018 Apr 9;33(4):570-580
pubmed: 29634945
Cell Metab. 2015 Dec 1;22(6):971-82
pubmed: 26552345
Arch Latinoam Nutr. 1991 Dec;41(4):569-83
pubmed: 1841538
Clin Gastroenterol Hepatol. 2019 Jan;17(2):275-289
pubmed: 30031175
Plant Foods Hum Nutr. 1995 Dec;48(4):349-65
pubmed: 8882373
Cell. 2018 Mar 8;172(6):1198-1215
pubmed: 29522742
Am J Clin Nutr. 2011 May;93(5):1062-72
pubmed: 21389180
Methods Mol Biol. 2018;1856:141-156
pubmed: 30178250
Trends Cancer. 2019 Sep;5(9):521-524
pubmed: 31474355
Microbiome. 2017 Nov 16;5(1):151
pubmed: 29145891
Science. 2011 Oct 7;334(6052):105-8
pubmed: 21885731
N Z Med J. 2012 Jun 08;125(1356):27-37
pubmed: 22729056
Br J Nutr. 2014 May;111(9):1549-63
pubmed: 24521520
Ann N Y Acad Sci. 2012 Oct;1271:82-7
pubmed: 23050968
PLoS Biol. 2012;10(8):e1001377
pubmed: 22904687
Arterioscler Thromb Vasc Biol. 2012 Aug;32(8):1766-70
pubmed: 22815342
Nat Commun. 2015 Apr 28;6:6342
pubmed: 25919227
Nutrients. 2018 Dec 22;11(1):
pubmed: 30583518
Nat Rev Microbiol. 2014 Oct;12(10):661-72
pubmed: 25198138
Proc Nutr Soc. 2012 Feb;71(1):181-9
pubmed: 22051112
Int J Obes (Lond). 2013 Feb;37(2):317-9
pubmed: 22410961
Am J Epidemiol. 2006 Feb 1;163(3):279-88
pubmed: 16339051
Curr Nutr Food Sci. 2014 May;10(2):112-119
pubmed: 25009453
Proc Nutr Soc. 2013 Feb;72(1):178-88
pubmed: 23174203
J Phys Act Health. 2008;5 Suppl 1:S30-44
pubmed: 18364524
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Clin Cancer Res. 2011 Apr 15;17(8):2444-50
pubmed: 21270110
Nat Rev Gastroenterol Hepatol. 2018 Nov;15(11):671-682
pubmed: 29844585
Semin Immunol. 2017 Aug;32:43-53
pubmed: 28982615
Eur J Oncol Nurs. 2015 Feb;19(1):1-6
pubmed: 25245710
CMAJ. 2014 May 13;186(8):E252-62
pubmed: 24710915
Nature. 2013 Aug 29;500(7464):541-6
pubmed: 23985870
Cancer Res. 2012 Jun 15;72(12):3029-37
pubmed: 22511581
Gut. 2007 Jul;56(7):1034-5
pubmed: 17566047
Mol Nutr Food Res. 2015 Apr;59(4):795-806
pubmed: 25641932
Nat Biotechnol. 2013 Sep;31(9):814-21
pubmed: 23975157
J Nutr. 2006 Jul;136(7):1896-903
pubmed: 16772456
Clin Nutr. 2019 Feb;38(1):348-356
pubmed: 29352655
Cancer Lett. 2013 Mar 1;330(1):1-10
pubmed: 23201597
Cell Metab. 2015 Aug 4;22(2):320-31
pubmed: 26244934
J Acad Nutr Diet. 2012 Aug;112(8):1134-7
pubmed: 22704899
Nat Rev Gastroenterol Hepatol. 2017 Jun;14(6):321-322
pubmed: 28442782
Public Health Nutr. 2006 Sep;9(6):755-62
pubmed: 16925881
FASEB J. 2013 Mar;27(3):1012-22
pubmed: 23165986
Nature. 2016 Jan 14;529(7585):212-5
pubmed: 26762459
J Transl Med. 2017 Apr 8;15(1):73
pubmed: 28388917
Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):439-44
pubmed: 24367073
Cancer Lett. 2015 Jan 28;356(2 Pt A):273-80
pubmed: 24614287